Worldwide Clinical Trials and Science 37® Partner to Advance Agile Clinical Trials™ and Accelerate Study Timelines
January 18 2022 - 7:55AM
Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading
global, midsized, full-service contract research organization (CRO)
and Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical
Trial Operating System™, today announced a collaboration to enable
enhanced decentralized clinical trial delivery in which patient
visits for the provision of healthcare or trial assessments and
laboratory tests are localized in the patient’s community. With
this new partnership, Worldwide will leverage Science 37’s
Operating System—bringing biopharmaceutical sponsors an end-to-end
technology platform and specialized networks solutions for faster
and more patient-centric clinical trial execution.
As sponsors continue to explore ways to drive accelerated study
timelines and bring trials closer to patients, use of decentralized
techniques and approaches are leading to increased agile (or
hybrid) clinical trial designs. Enabled by technology, agile
clinical trials can alleviate patient burdens—helping drive
efficiency, reduce costs, and increase patient participation by
incorporating the best elements of traditional and decentralized
approaches.
“Bringing clinical trials closer to patients and making it
easier for them to participate with more patient-centric approaches
are crucial imperatives for Worldwide Clinical Trials,” said Jeff
Zucker, Senior Vice President, DCT Solutions & Trial
Optimization. “Our powerful partnership with Science 37 adds its
industry-leading Operating System to our offering for sponsors and
enables more flexible solutions to support patients from
anywhere—an increasingly important option for our key therapeutic
areas of oncology, neurology, metabolic, and rare diseases.”
Through this partnership, Worldwide Clinical Trials becomes part
of the Science 37 CRO Certified network, designed to empower CROs
with access, training, and commercial support to successfully
deliver decentralized clinical studies at scale.
“Working with Worldwide strengthens our ability to enable
universal access to patients and providers and brings our Operating
System to more sponsors for faster enrollment, greater retention,
and a more representative patient population,” said Steve Geffon,
Chief Commercial Officer of Science 37. “Our technology platform
and specialized networks of patient communities, telemedicine
investigators, mobile nurses, and remote coordinators enables
Worldwide to provide more decentralization clinical trial
capability for agile clinical trial designs that support patients
and accelerate the development of treatments that impact people’s
lives.”
About Worldwide Clinical TrialsWorldwide
Clinical Trials is a global midsize contract research organization
(CRO) that provides top-performing preclinical and Phase I-IV
clinical development services to the biotechnology and
pharmaceutical industries.
Founded in 1986 by physicians committed to advancing medical
science, our full-service clinical experience ranges from early
phase and bioanalytical sciences through late phase studies, post
approval and real-world evidence. Major therapeutic areas of focus
include cardiovascular, metabolic, neuroscience, oncology and rare
diseases. With infrastructure spanning 60 countries and offices in
North and South America, Eastern and Western Europe, Russia and
Asia, Worldwide is powered by its more than 2,600 employee
experts.
For more information please visit www.worldwide.com or connect
with us on Twitter, LinkedIn, Facebook, and Instagram.
About Science 37Science 37 Holdings, Inc.’s
(Nasdaq: SNCE) mission is to enable universal access to clinical
research—making it easier for patients and providers to participate
from anywhere and helping to accelerate the development of
treatments that impact patient lives. As a pioneer of decentralized
clinical trials, the Science 37 Agile Clinical Trial Operating
System (OS) supports today’s more agile clinical research designs
with its full stack, end-to-end technology platform and specialized
networks of patient communities, telemedicine investigators, mobile
nurses, remote coordinators and connected devices. Configurable to
enable almost any study type, the Science 37 OS enables up to 15x
faster enrollment, 28% better retention and 3x more diverse patient
population with industry-leading workflow orchestration, evidence
generation and data harmonization. For more information, visit
https://www.science37.com.
MEDIA INQUIRIES:
Worldwide Clinical TrialsKaren HagensVP, Global
Corporate CommunicationsKaren.hagens@worldwide.com
Science 37Margie KoomanVP, Marketing &
Communicationspr@science37.com
INVESTOR RELATIONS:Caroline
PaulGilmartinInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024